Alberto Chiappori

16.5k total citations · 3 hit papers
171 papers, 5.9k citations indexed

About

Alberto Chiappori is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Alberto Chiappori has authored 171 papers receiving a total of 5.9k indexed citations (citations by other indexed papers that have themselves been cited), including 128 papers in Oncology, 96 papers in Pulmonary and Respiratory Medicine and 49 papers in Molecular Biology. Recurrent topics in Alberto Chiappori's work include Lung Cancer Treatments and Mutations (85 papers), Lung Cancer Research Studies (68 papers) and Cancer Immunotherapy and Biomarkers (34 papers). Alberto Chiappori is often cited by papers focused on Lung Cancer Treatments and Mutations (85 papers), Lung Cancer Research Studies (68 papers) and Cancer Immunotherapy and Biomarkers (34 papers). Alberto Chiappori collaborates with scholars based in United States, France and Japan. Alberto Chiappori's co-authors include Scott Antonia, George R. Simon, Dmitry I. Gabrilovich, Gerold Bepler, Eric B. Haura, Jhanelle E. Gray, Shirish M. Gadgeel, Tawee Tanvetyanon, Charles C. Williams and Dung‐Tsa Chen and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Alberto Chiappori

164 papers receiving 5.8k citations

Hit Papers

Safety and activity of alectinib against systemic disease... 2014 2026 2018 2022 2014 2015 2019 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study
    2014 538 citations Shirish M. Gadgeel, Leena Gandhi et al. profile →
  2. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial
    2015 462 citations Alice T. Shaw, Leena Gandhi et al. profile →
  3. Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC
    2019 305 citations Jhanelle E. Gray, Alberto Chiappori et al. Journal of Thoracic Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Alberto Chiappori United States 38 3.6k 2.6k 2.2k 1.0k 615 171 5.9k
Martin Sebastian Germany 27 4.1k 1.1× 3.3k 1.3× 1.7k 0.8× 945 0.9× 930 1.5× 117 5.8k
Hiroshi Nokihara Japan 40 3.9k 1.1× 3.3k 1.3× 1.7k 0.8× 484 0.5× 935 1.5× 237 5.9k
Ichiro Kinoshita Japan 38 3.4k 0.9× 2.0k 0.8× 2.0k 0.9× 1.7k 1.6× 835 1.4× 148 5.8k
Sophie Postel‐Vinay France 37 3.2k 0.9× 1.7k 0.7× 2.2k 1.0× 951 0.9× 936 1.5× 117 5.7k
Noemı́ Reguart Spain 41 2.9k 0.8× 2.6k 1.0× 2.5k 1.2× 419 0.4× 875 1.4× 175 5.5k
Juanita Lopez United Kingdom 28 2.6k 0.7× 1.3k 0.5× 1.9k 0.9× 1.2k 1.2× 821 1.3× 144 4.9k
Niels Reinmuth Germany 43 5.0k 1.4× 2.9k 1.1× 2.9k 1.4× 851 0.8× 1.5k 2.4× 196 7.9k
Rita Chiari Italy 36 2.6k 0.7× 2.4k 0.9× 1.4k 0.6× 452 0.4× 900 1.5× 140 4.2k
Michael Millward Australia 48 4.4k 1.2× 1.9k 0.7× 3.2k 1.5× 1.2k 1.2× 1.3k 2.1× 277 7.7k
Patrick M. Forde United States 40 4.0k 1.1× 2.7k 1.0× 934 0.4× 1.1k 1.1× 645 1.0× 186 5.7k

Countries citing papers authored by Alberto Chiappori

Since Specialization
Citations

This map shows the geographic impact of Alberto Chiappori's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alberto Chiappori with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alberto Chiappori more than expected).

Fields of papers citing papers by Alberto Chiappori

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alberto Chiappori. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alberto Chiappori. The network helps show where Alberto Chiappori may publish in the future.

Co-authorship network of co-authors of Alberto Chiappori

This figure shows the co-authorship network connecting the top 25 collaborators of Alberto Chiappori. A scholar is included among the top collaborators of Alberto Chiappori based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alberto Chiappori. Alberto Chiappori is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Owonikoko, Taofeek K., Alberto Chiappori, Ryan D. Gentzler, et al.. (2024). Alisertib in patients with extensive-stage small-cell lung cancer: The phase 2 ALISCA-Lung1 study.. Journal of Clinical Oncology. 42(16_suppl). TPS8128–TPS8128. 1 indexed citations
2.
Kim, Yongsoo, Barzin Y. Nabet, Huann‐Sheng Chen, et al.. (2024). MA17.11 NOTCH1 Expression Is Associated with Overall Survival in Small Cell Lung Cancer Patients Treated with Atezolizumab in IMpower133. Journal of Thoracic Oncology. 19(10). S127–S127.
3.
Thapa, Ram, Michael Shafique, Andreas Saltos, et al.. (2023). Osimertinib vs. afatinib as first-line treatment for patients with metastatic non-small cell lung cancer with an EGFR exon 19 deletion or exon 21 L858R mutation. Journal of Thoracic Disease. 15(11). 6115–6125. 4 indexed citations
4.
5.
Chen, Dung‐Tsa, Andreas Saltos, Trevor Rose, et al.. (2023). Early Adverse Event Derived Biomarkers in Predicting Clinical Outcomes in Patients with Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy. Cancers. 15(9). 2521–2521. 2 indexed citations
6.
Saltos, Andreas, Ben Creelan, Tawee Tanvetyanon, et al.. (2023). A phase I/IB trial of binimetinib in combination with erlotinib in NSCLC harboring activating KRAS or EGFR mutations. Lung Cancer. 183. 107313–107313. 3 indexed citations
7.
Hamid, Omid, Alberto Chiappori, John A. Thompson, et al.. (2022). First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors. Journal for ImmunoTherapy of Cancer. 10(10). e005471–e005471. 37 indexed citations
8.
Chiappori, Alberto, Ben Creelan, Tawee Tanvetyanon, et al.. (2022). Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non–Small Cell Lung Cancer. Clinical Cancer Research. 28(11). 2313–2320. 50 indexed citations
9.
Chen, Dung‐Tsa, Wenyaw Chan, Zachary Thompson, et al.. (2021). Utilization of target lesion heterogeneity for treatment efficacy assessment in late stage lung cancer. PLoS ONE. 16(7). e0252041–e0252041. 4 indexed citations
10.
Saltos, Andreas, Michael Shafique, & Alberto Chiappori. (2020). Update on the Biology, Management, and Treatment of Small Cell Lung Cancer (SCLC). Frontiers in Oncology. 10. 1074–1074. 103 indexed citations
11.
Wakelee, Heather A., Karen L. Reckamp, Ticiana Leal, et al.. (2019). P1.14-32 Rash and Efficacy in Anaplastic Lymphoma Kinase Positive (ALK+) Non-Small Cell Lung Cancer Patients Treated with Ensartinib. Journal of Thoracic Oncology. 14(10). S566–S566. 2 indexed citations
12.
Camidge, D. Ross, Shirish M. Gadgeel, Leena Gandhi, et al.. (2017). MA07.02 Updated Efficacy and Safety Data from the Phase 2 NP28761 Study of Alectinib in ALK-Positive Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology. 12(1). S378–S378. 10 indexed citations
13.
14.
15.
16.
Kumar, Virendra, Kavindra Nath, Claudia G. Berman, et al.. (2013). Variance of SUVs for FDG-PET/CT is Greater in Clinical Practice Than Under Ideal Study Settings. Clinical Nuclear Medicine. 38(3). 175–182. 64 indexed citations
17.
Gray, Jhanelle E., Christopher Cubitt, Shumin Zhang, & Alberto Chiappori. (2012). Combination of HDAC and topoisomerase inhibitors in small cell lung cancer. Cancer Biology & Therapy. 13(8). 614–622. 44 indexed citations
18.
Simon, George R., Anupama Sharma, Xueli Li, et al.. (2007). Feasibility and Efficacy of Molecular Analysis-Directed Individualized Therapy in Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 25(19). 2741–2746. 147 indexed citations
19.
Chiappori, Alberto, Peter Ellis, John Hamm, et al.. (2006). A Phase I Evaluation of Oral CI-1033 in Combination with Paclitaxel and Carboplatin as First-Line Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 1(9). 1010–1019. 12 indexed citations
20.
Lima, Caio M. Rocha & Alberto Chiappori. (2003). Treatment of relapsed small-cell lung cancer—a focus on the evolving role of topotecan. Lung Cancer. 40(3). 229–236. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Martin Sebastian Breakdown of academic impact, for papers by Hiroshi Nokihara Breakdown of academic impact, for papers by Ichiro Kinoshita Breakdown of academic impact, for papers by Sophie Postel‐Vinay Breakdown of academic impact, for papers by Noemı́ Reguart Breakdown of academic impact, for papers by Juanita Lopez Breakdown of academic impact, for papers by Niels Reinmuth Breakdown of academic impact, for papers by Rita Chiari Breakdown of academic impact, for papers by Michael Millward Breakdown of academic impact, for papers by Patrick M. Forde
Rankless by CCL
2026